Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures. Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled "Reverse Engineering of Digital Measures," was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools. Key messages: In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.

Reverse Engineering of Digital Measures: Inviting Patients to the Conversation / Clay, Ieuan; Peerenboom, Nele; Connors, Dana E; Bourke, Steven; Keogh, Alison; Wac, Katarzyna; Gur-Arie, Tova; Baker, Justin; Bull, Christopher; Cereatti, Andrea; Cormack, Francesca; Eggenspieler, Damien; Foschini, Luca; Ganea, Raluca; Groenen, Peter M A; Gusset, Nicole; Izmailova, Elena; Kanzler, Christoph M; Leyens, Lada; Lyden, Kate; Mueller, Arne; Nam, Julian; Ng, Wan-Fai; Nobbs, David; Orfaniotou, Foteini; Perumal, Thanneer Malai; Piwko, Wojciech; Ries, Anja; Scotland, Alf; Taptiklis, Nick; Torous, John; Vereijken, Beatrix; Xu, Shuai; Baltzer, Laurenz; Vetter, Thorsten; Goldhahn, Jörg; Hoffmann, Steven C. - In: DIGITAL BIOMARKERS. - ISSN 2504-110X. - ELETTRONICO. - 7:1(2023), pp. 28-44. [10.1159/000530413]

Reverse Engineering of Digital Measures: Inviting Patients to the Conversation

Cereatti, Andrea;
2023

Abstract

Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures. Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled "Reverse Engineering of Digital Measures," was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools. Key messages: In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.
2023
File in questo prodotto:
File Dimensione Formato  
Clay et al_2023_digital biomarkers.pdf

accesso aperto

Tipologia: 2a Post-print versione editoriale / Version of Record
Licenza: Creative commons
Dimensione 888.28 kB
Formato Adobe PDF
888.28 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11583/2981319